FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Patrick Harriott

Research Profile

Chemicals & Drugs

Living Beings

Genes & Molecular Sequences

Amino Acid Sequences

Procedures

Electrospray Ionization Mass Spectrometry

Disorders

Anatomy

Islets of Langerhans

Co-author Network

Publications

TOP 3
Victor A Gault; Patrick Harriott; Barry D Kerr; Peter R Flatt
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
George R A Cathcart; Derek Quinn; Brett Greer; Patrick Harriott; John F Lynas; Brendan F Gilmore; Brian Walker
Novel inhibitors of the Pseudomonas aeruginosa virulence factor LasB: a potential therapeutic approach for the attenuation of virulence mechanisms in pseudomonal infection.
Diarmaid J Murphy; Brian Walker; Brett Greer; Patrick Harriott; S Lorraine Martin
A modified Tat peptide for selective intracellular delivery of macromolecules.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Patrick Harriott (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Victor A Gault; Patrick Harriott; Barry D Kerr; Peter R Flatt
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Clinical science (London, England : 1979) 2011;121(3):107-17.
2011: George R A Cathcart; Derek Quinn; Brett Greer; Patrick Harriott; John F Lynas; Brendan F Gilmore; Brian Walker
Novel inhibitors of the Pseudomonas aeruginosa virulence factor LasB: a potential therapeutic approach for the attenuation of virulence mechanisms in pseudomonal infection.
Antimicrobial agents and chemotherapy 2011;55(6):2670-8.
2011: Diarmaid J Murphy; Brian Walker; Brett Greer; Patrick Harriott; S Lorraine Martin
A modified Tat peptide for selective intracellular delivery of macromolecules.
The Journal of pharmacy and pharmacology 2011;63(5):611-8.
2010: Paula L McClean; Victor A Gault; Patrick Harriott; Christian Hölscher
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
European journal of pharmacology 2010;630(1-3):158-62.
2009: George R Cathcart; Brendan F Gilmore; Brett Greer; Patrick Harriott; Brian Walker
Inhibitor profiling of the Pseudomonas aeruginosa virulence factor LasB using N-alpha mercaptoamide template-based inhibitors.
Bioorganic & medicinal chemistry letters 2009;19(21):6230-2.
2008: Fionnuala T Lundy; John Nelson; Derek Lockhart; Brett Greer; Patrick Harriott; John J Marley
Antimicrobial activity of truncated alpha-defensin (human neutrophil peptide (HNP)-1) analogues without disulphide bridges.
Molecular immunology 2008;45(1):190-3.
2007: Nigel Irwin; Paula L McClean; Roslyn S Cassidy; Finbarr P M O'Harte; Brian D Green; Victor A Gault; Patrick Harriott; Peter R Flatt
Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.
Diabetes/metabolism research and reviews 2007;23(7):572-9.
2007: Nigel Irwin; Paula L McClean; Finbarr P M O'Harte; Victor A Gault; Patrick Harriott; Peter R Flatt
Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.
Diabetologia 2007;50(7):1532-40.
2007: Finbarr P M O'Harte; Kerry Hunter; Victor A Gault; Nigel Irwin; Brian D Green; Brett Greer; Patrick Harriott; Clifford J Bailey; Peter R Flatt
Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.
American journal of physiology. Endocrinology and metabolism 2007;292(6):E1674-82.
2007: Simon Gengler; Victor A Gault; Patrick Harriott; Christian Hölscher
Impairments of hippocampal synaptic plasticity induced by aggregated beta-amyloid (25-35) are dependent on stimulation-protocol and genetic background.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 2007;179(4):621-30.
2007: Victor A Gault; Kerry Hunter; Nigel Irwin; Brian D Green; Brett Greer; Patrick Harriott; Finbarr P M O'Harte; Peter R Flatt
Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists.
Archives of biochemistry and biophysics 2007;461(2):263-74.
2007: Christian Holscher; Simon Gengler; Victor A Gault; Patrick Harriott; Hanspeter A Mallot
Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning.
European journal of pharmacology 2007;561(1-3):85-90.
2007: Nigel Irwin; Paula L McClean; Patrick Harriott; Peter R Flatt
Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice.
Experimental gerontology 2007;42(4):296-300.
2007: Victor A Gault; Kerry Hunter; Nigel Irwin; Brett Greer; Brian D Green; Patrick Harriott; Finbarr P M O'Harte; Peter R Flatt
Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes.
Biological chemistry 2007;388(2):173-9.
2006: Jeremy C Parker; Kerry S Lavery; Nigel Irwin; Brian D Green; Brett Greer; Patrick Harriott; Finbarr P M O'Harte; Victor A Gault; Peter R Flatt
Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
The Journal of endocrinology 2006;191(1):93-100.
2006: Nigel Irwin; Gillian C Clarke; Brian D Green; Brett Greer; Patrick Harriott; Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Biochemical pharmacology 2006;72(6):719-28.
2006: Brian D Green; Kerry S Lavery; Nigel Irwin; Finbarr P M O'Harte; Patrick Harriott; Brett Greer; Clifford J Bailey; Peter R Flatt
Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
The Journal of pharmacology and experimental therapeutics 2006;318(2):914-21.
2006: Brendan F Gilmore; John F Lynas; Patrick Harriott; Adrienne Healy; Brian Walker
Peptides containing acylated C-terminal gem diamines: novel irreversible inactivators of the cysteine and serine proteinases.
Chemical biology & drug design 2006;67(5):364-9.
2006: Nigel Irwin; Brian D Green; Victor A Gault; Roslyn S Cassidy; Finbarr P M O'Harte; Patrick Harriott; Peter R Flatt
Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice.
Peptides 2006;27(4):893-900.
2006: Nigel Irwin; Finbarr P M O'Harte; Victor A Gault; Brian D Green; Brett Greer; Patrick Harriott; Clifford J Bailey; Peter R Flatt
GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.
Journal of medicinal chemistry 2006;49(3):1047-54.
2005: Nigel Irwin; Brian D Green; mark mooney; Brett Greer; Patrick Harriott; Clifford J Bailey; Victor A Gault; Finbarr P M O'Harte; Peter R Flatt
A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.
The Journal of pharmacology and experimental therapeutics 2005;314(3):1187-94.
2005: Brendan F Gilmore; Patrick Harriott; Brian Walker
The inactivation of bovine cathepsin B by novel N-chloro-acetyl-dipeptides: application of the Houghten 'tea bag' methodology to inhibitor synthesis.
Biochemical and biophysical research communications 2005;333(4):1284-8.
2005: Victor A Gault; Nigel Irwin; Brian D Green; Jane T McCluskey; Brett Greer; Clifford J Bailey; Patrick Harriott; Finbarr P M O'Harte; Peter R Flatt
Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.
Diabetes 2005;54(8):2436-46.
2005: Nigel Irwin; Victor A Gault; Brian D Green; Brett Greer; Patrick Harriott; Clifford J Bailey; Peter R Flatt; Finbarr P M O'Harte
Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).
Biological chemistry 2005;386(7):679-87.
2005: Nigel Irwin; Brian D Green; Victor A Gault; Brett Greer; Patrick Harriott; Clifford J Bailey; Peter R Flatt; Finbarr P M O'Harte
Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.
Journal of medicinal chemistry 2005;48(4):1244-50.
2004: Judith E Humphries; Michael J Kimber; Yi-Wen Barton; Walter Hsu; Nikki J Marks; Brett Greer; Patrick Harriott; Aaron G Maule; Tim A Day
Structure and bioactivity of neuropeptide F from the human parasites Schistosoma mansoni and Schistosoma japonicum.
The Journal of biological chemistry 2004;279(38):39880-5.
2004: Nigel Irwin; Victor A Gault; Brian D Green; Brett Greer; Jane T McCluskey; Patrick Harriott; Finbarr P M O'Harte; Peter R Flatt
Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.
Biological chemistry 2004;385(9):845-52.
2004: Brian D Green; Victor A Gault; Peter R Flatt; Patrick Harriott; Brett Greer; Finbarr P M O'Harte
Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Archives of biochemistry and biophysics 2004;428(2):136-43.
2004: Omar M A El-Agnaf; Katerina E Paleologou; Brett Greer; Abdulmawala M Abogrein; Jenny E King; Sultan A Salem; Nigel J Fullwood; Fiona E Benson; Rebecca Hewitt; Kirstie J Ford; Francis L Martin; Patrick Harriott; Mark Cookson; David Allsop
A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(11):1315-7.
2004: Deirdre Larkin; Derek Murphy; Dermot Reilly; Martha Cahill; Ellen Sattler; Patrick Harriott; Dolores J Cahill; Niamh Moran
ICln, a novel integrin alphaIIbbeta3-associated protein, functionally regulates platelet activation.
The Journal of biological chemistry 2004;279(26):27286-93.
2004: Brian D Green; mark mooney; Victor A Gault; Nigel Irwin; Clifford J Bailey; Patrick Harriott; Brett Greer; Finbarr P M O'Harte; Peter R Flatt
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
The Journal of endocrinology 2004;180(3):379-88.
2004: Brian D Green; Victor A Gault; mark mooney; Nigel Irwin; Patrick Harriott; Brett Greer; Clifford J Bailey; Finbarr P M O'Harte; Peter R Flatt
Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
Biological chemistry 2004;385(2):169-77.
2004: Brian D Green; mark mooney; Victor A Gault; Nigel Irwin; Clifford J Bailey; Patrick Harriott; Brett Greer; Peter R Flatt; Finbarr P M O'Harte
Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
Metabolism: clinical and experimental 2004;53(2):252-9.
2003: Brian D Green; Victor A Gault; Nigel Irwin; mark mooney; Clifford J Bailey; Patrick Harriott; Brett Greer; Peter R Flatt; Finbarr P M O'Harte
Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Biological chemistry 2003;384(12):1543-51.
2003: Brian D Green; Victor A Gault; mark mooney; Nigel Irwin; Clifford J Bailey; Patrick Harriott; Brett Greer; Peter R Flatt; Finbarr P M O'Harte
Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
Journal of molecular endocrinology 2003;31(3):529-40.
2003: Victor A Gault; Finbarr P M O'Harte; Patrick Harriott; Peter R Flatt
Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo.
Metabolism: clinical and experimental 2003;52(6):679-87.
2003: Victor A Gault; Finbarr P M O'Harte; Patrick Harriott; mark mooney; Brian D Green; Peter R Flatt
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Diabetologia 2003;46(2):222-30.
2003: Victor A Gault; Nigel Irwin; Patrick Harriott; Peter R Flatt; Finbarr P M O'Harte
DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP.
Cell biology international 2003;27(1):41-6.
2003: Victor A Gault; Peter R Flatt; Patrick Harriott; mark mooney; Clifford J Bailey; Finbarr P M O'Harte
Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide.
The Journal of endocrinology 2003;176(1):133-41.
2002: Victor A Gault; Jeremy C Parker; Patrick Harriott; Peter R Flatt; Finbarr P M O'Harte
Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo.
The Journal of endocrinology 2002;175(2):525-33.
2002: Martin J Quinn; John Fullard; Steven Kerrigan; Patrick Harriott; Dermot Cox; Desmond J Fitzgerald
Characterization of a ligand-attenuated binding site on glycoprotein IIb/IIIa.
Thrombosis and haemostasis 2002;88(5):811-6.
2002: Victor A Gault; Peter R Flatt; Clifford J Bailey; Patrick Harriott; Brett Greer; mark mooney; Finbarr P M O'Harte
Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
The Biochemical journal 2002;367(Pt 3):913-20.
2002: Victor A Gault; Patrick Harriott; Peter R Flatt; Finbarr P M O'Harte
Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.
Bioscience reports 2002;22(5-6):523-8.
2002: Mark T Fox; Brett Greer; Jill Lawson; Adrienne Healy; Patrick Harriott
Kinetic analysis of the cleavage of human protease-activated receptor-1 / 2 / 3 and 4 using quenched-fluorescent peptide substrates.
Protein and peptide letters 2002;9(5):387-97.
2002: Finbarr P M O'Harte; Victor A Gault; Jeremy C Parker; Patrick Harriott; mark mooney; Clifford J Bailey; Peter R Flatt
Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
Diabetologia 2002;45(9):1281-91.
2002: Victor A Gault; Finbarr P M O'Harte; Patrick Harriott; Peter R Flatt
Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.
Biochemical and biophysical research communications 2002;290(5):1420-6.
2002: Dorota Gebarowska; Alan Stitt; Tom A Gardiner; Patrick Harriott; Brett Greer; John Nelson
Synthetic peptides interacting with the 67-kd laminin receptor can reduce retinal ischemia and inhibit hypoxia-induced retinal neovascularization.
The American journal of pathology 2002;160(1):307-13.
2001: Aine M McKillop; mark mooney; Patrick Harriott; Peter R Flatt; Finbarr P M O'Harte
Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay.
Biochemical and biophysical research communications 2001;286(3):524-8.
2000: W N Scott; NV McFerran; Patrick Harriott; B Walker; J Nelson
Development of laminin receptor agonists: identification of important functional residues by alanine scanning.
Biochimica et biophysica acta 2000;1481(1):25-36.
2000: Angela M Bodles; David J S Guthrie; Patrick Harriott; P Campbell; G Brent Irvine
Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils.
European journal of biochemistry / FEBS 2000;267(8):2186-94.
1998: Omar M A El-Agnaf; Angela M Bodles; David J S Guthrie; Patrick Harriott; G Brent Irvine
The N-terminal region of non-A beta component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils.
European journal of biochemistry / FEBS 1998;258(1):157-63.
1998: L Hou; Supriya Kapas; AT Cruchley; Marion G Macey; Patrick Harriott; Carla Chinni; SR Stone; Gareth L Howells
Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro.
Immunology 1998;94(3):356-62.
1998: L Hou; S Ravenall; Marion G Macey; Patrick Harriott; Supriya Kapas; Gareth L Howells
Protease-activated receptors and their role in IL-6 and NF-IL-6 expression in human gingival fibroblasts.
Journal of periodontal research 1998;33(4):205-11.
1998: Alan Stitt; D McKenna; David A C Simpson; Tom A Gardiner; Patrick Harriott; Desmond B Archer; J Nelson
The 67-kd laminin receptor is preferentially expressed by proliferating retinal vessels in a murine model of ischemic retinopathy.
The American journal of pathology 1998;152(5):1359-65.
1998: John F Lynas; Patrick Harriott; Adrienne Healy; M Anthony McKervey; Brian Walker
Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl alpha-keto aldehydes (glyoxals).
Bioorganic & medicinal chemistry letters 1998;8(4):373-8.
1998: B P McIlhatton; P E Erwin; Patrick Harriott; NV McFerran; G Brian Wisdom; M Isla Halliday
Development and characterisation of anti-peptide antibodies to rat lipopolysaccharide binding protein.
Biochemical Society transactions 1998;26(1):S51.
1998: G Brent Irvine; Omar M A El-Agnaf; Angela M Bodles; David J S Guthrie; Patrick Harriott
Studies on the aggregation and secondary structure of peptides derived from non-A beta component of Alzheimer's disease amyloid.
Biochemical Society transactions 1998;26(1):S36.
1997: Mark T Fox; Patrick Harriott; B Walker; SR Stone
Identification of potential activators of proteinase-activated receptor-2.
FEBS letters 1997;417(3):267-9.
1997: Gareth L Howells; Marion G Macey; Carla Chinni; L Hou; Mark T Fox; Patrick Harriott; SR Stone
Proteinase-activated receptor-2: expression by human neutrophils.
Journal of cell science 1997;110 ( Pt 7)():881-7.
1996: J Nelson; W N Scott; W E Allen; D J Wilson; Patrick Harriott; NV McFerran; B Walker
Murine epidermal growth factor peptide (33-42) binds to a YIGSR-specific laminin receptor on both tumor and endothelial cells.
The Journal of biological chemistry 1996;271(42):26179-86.
1994: David J S Guthrie; O el-Agnaf; Patrick Harriott; G Brent Irvine; B Walker
Successful syntheses of beta amyloid-(25-35)-peptide: a difficult sequence by N-(9-fluorenylmethoxycarbonyl) chemistry.
Biochemical Society transactions 1994;22(4):1052-4.